What is Valencell?
Valencell is at the forefront of digital health innovation, focusing on empowering individuals with chronic disease management tools, particularly for hypertension. The company is distinguished by its development of a portable, cuffless blood pressure measuring device, integrated with a mobile application for seamless health monitoring. With a robust portfolio of over 150 patents, Valencell demonstrates a deep commitment to advancing biometric sensor technology and analytics. Their mission centers on enabling users to adopt healthier lifestyles through reliable trend tracking and proactive health management, positioning them as a key player in the wearable health technology market.
How much funding has Valencell raised?
Valencell has raised a total of $38.6M across 8 funding rounds:
Series B
$5.5M
Series C
$7M
Private Equity
$2.6M
Series D
$11M
Series E
$10.5M
Debt
$350K
Debt
$647K
Series B (2011): $5.5M led by True Ventures and TDF Ventures
Series C (2014): $7M supported by TDF Ventures and True Ventures
Private Equity (2015): $2.6M, investors not publicly disclosed
Series D (2016): $11M backed by GII Tech, TDF Ventures, and WSJ Joshua Fund
Series E (2018): $10.5M with participation from Sonion a/s, TDF Ventures, WSJ Joshua Fund, and GII LLC
Debt (2020): $350K led by PPP
Debt (2021): $647K supported by PPP
Key Investors in Valencell
TDF Ventures
TDF Ventures is an early-stage venture capital firm focused on startups serving enterprise markets in infrastructure, software, and services.
True Ventures
True Ventures is a founder-first venture capital firm that partners with early-stage technology and AI-driven companies, providing capital and guidance.
GII Tech
GII Tech is an entity that has participated in strategic funding rounds, indicating an interest in technology and innovation sectors.
What's next for Valencell?
The substantial enterprise-level funding and recent strategic investment signal a pivotal phase for Valencell. This capital injection is anticipated to fuel further research and development, particularly in refining their cuffless blood pressure technology and expanding the capabilities of their mobile health platform. Strategic partnerships and market expansion are likely next steps, aiming to solidify Valencell's position as a leader in digital health solutions for chronic disease management. The company's strong patent foundation suggests a continued focus on innovation and intellectual property protection as it scales its operations and product offerings.
See full Valencell company page
